Shots:
- Xbrane & STADA have signed an exclusive license agreement with Valorum Biologics to commercialize Xlucane, biosimilar of ranibizumab, across the US
- As per the agreement, both companies will complete the regulatory approval process; Xbrane to handle commercial manufacturing & supply. Post approval, Valorum will take care of sales, marketing & other commercial activities of LUCAMZI (Xlucane)
- Valorum will make a payment of $45M as license fee incl. regulatory & sales milestones plus sales-based royalties, to be shared b/w both. Furthermore, as per separate agreement, product will be supplied by Xbrane to Valorum at double-digit mark-up over cost of goods sold (CoGS)
Ref: Xbrane | Image: Xbrane & STADA| Press Release
Related News:- Boehringer Ingelheim Partners with Quallent Pharmaceuticals to Expand the Access of Cyltezo (Biosimilar, Humira)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
